
MHRA announces corporate plan for 2023-2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has published its corporate plan for the next three years, featuring a focus on patient access to innovation.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has published its corporate plan for the next three years, featuring a focus on patient access to innovation.
Following the European Commission’s 6 January vote to extend the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) transition period, the European Parliament (EP) adopted the proposal on 16 February 2023.
The Government has published its response to the consultation on proposals for changes to the Medicines and Healthcare products Regulatory Agency’s (MHRA) statutory fees.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the European Commission Decision Reliance Procedure (ECDRP) has been extended to 31 December 2023. After that a new international recognition framework will be instituted, from 1 January 2024.